Opioid-Induced Hypogonadism

Mechanism and Prevalence

Long-term opioid therapy most commonly causes hypogonadism through suppression of the hypothalamic-pituitary-gonadal axis, manifesting as testosterone deficiency with associated fatigue, depression, decreased libido, and increased fracture risk, as noted by the American Geriatrics Society 1, 2
The risk of hypogonadism increases with higher opioid doses, with an adjusted odds ratio of 1.6 (95% CI = 1.0–2.4) for requiring erectile dysfunction medications or testosterone replacement at doses ≥120 MME/day compared to lower doses, according to the Centers for Disease Control and Prevention 3, 4, 5

Fatigue, depression, and anxiety are common symptoms of opioid-induced hypogonadism in men, as reported by the American Geriatrics Society 1, 6

Chronic opioid therapy disrupts the hypothalamic-pituitary-gonadal axis, resulting in central suppression of gonadotropin-releasing hormone and subsequent testosterone deficiency, as reported by the Journal of Clinical Oncology and the National Comprehensive Cancer Network 7, 8, 9

Testosterone replacement therapy may be considered after careful consideration of risks and benefits, as suggested by the Journal of Clinical Oncology 7
The American College of Clinical Oncology recommends that testosterone deficiency through hypothalamic-pituitary-gonadal axis suppression is the predominant and most clinically significant endocrine abnormality in chronic opioid therapy 7, 8

Opioid‑induced hypogonadism is the most common and clinically significant endocrine disorder linked to sustained opioid use, arising from suppression of the hypothalamic‑pituitary‑gonadal axis and resulting in testosterone deficiency in both men and women. 10

Patients receiving ≥120 mg morphine‑equivalent dose per day have a 1.6‑fold higher odds (95 % CI = 1.0–2.4) of requiring erectile‑dysfunction medication or testosterone replacement compared with those on lower opioid doses, indicating a dose‑dependent risk. 11

In individuals with opioid‑induced testosterone deficiency, common symptoms include fatigue, depression, reduced libido, and impotence, which may be misattributed to chronic pain rather than endocrine dysfunction. [10][12]

Prolonged hypogonadism secondary to opioid therapy leads directly to osteoporosis and osteopenia; the American Society of Clinical Oncology classifies these bone‑density losses as persistent adverse effects of long‑term opioid use. 10

Depression and anxiety frequently accompany opioid‑induced hypogonadism, contributing to the overall symptom burden in patients with chronic pain. 12

Testosterone replacement therapy can be considered after a careful risk‑benefit assessment for patients with confirmed opioid‑induced hypogonadism, although it does not correct the underlying hormonal suppression caused by opioids. 10